Press release
Precision Antibody Leads the Future of Antibody-Based Therapeutics by Partnering Up with Premier Global Drug Discovery Forum
Pioneering new frontiers in drug discovery, Precision Antibody joins forces with the 17th Drug Discovery Strategic Summit
The 17th DDSS is designed to promote collaboration, knowledge-sharing, and innovation in the pharmaceutical and biotech industries. The summit offers an immersive experience that includes keynote presentations, panel discussions, one-to-one meetings, and an exhibition showcasing the latest advancements in drug discovery. By embracing strategic agility and foresight, the summit helps professionals navigate the evolving landscape of drug discovery, equipping them with the tools to drive progress in this critical field.
As a sponsor of this esteemed event, Precision Antibody is not just participating, but leading the charge in advancing the frontiers of drug discovery, particularly in the area of antibody-based therapeutics. The company's extensive suite of custom services, including the discovery and development of high-affinity, specific monoclonal antibodies, including fully human monoclonal antibodies is tailored to meet the needs of the pharmaceutical and biotech industries.
"We are thrilled to be part of the 17th Drug Discovery Strategic Summit," said Dr. Jun Hayashi, President of Precision Antibody. "This summit offers a unique opportunity to engage with the brightest minds in the field and discuss how our antibody technologies can support the acceleration of novel therapeutic development. It's an exciting time to be involved in drug discovery, and we're eager to share our expertise and contribute to the conversation." Precision Antibody fully human monoclonal antibody technology will be featured in a presentation on October 23rd by Dr. Ginette Serrero, CEO, entitled: "Development of fully human antibody using transgenic TC mice. Fully human ADC for a novel cancer target".
What to Expect at the Summit
The two-day summit is packed with exciting events designed to inspire and inform, including:
• 4 Panel Discussions: Featuring C-level executives, the panels will explore key issues and challenges in drug discovery, from early-stage research to the latest advancements in therapeutic technologies.
• 35+ Expert Speakers: Industry leaders and visionaries will deliver innovative keynote presentations, offering insights into the evolving landscape of drug discovery and development.
• 10+ Hours of Networking: With dedicated networking sessions, attendees will have ample opportunities to connect with potential collaborators, exchange ideas, and build lasting partnerships.
• 100+ One-to-One Meetings: These personalized sessions will provide the perfect platform for focused discussions on potential collaborations, new business opportunities, and innovative solutions.
• Exhibition Booths: Cutting-edge technologies and services will be on display from global industry leaders, including Precision Antibody, offering attendees the chance to explore new innovations in drug discovery.
Precision Antibody's Solutions for Drug Discovery
Precision Antibody has long been recognized as a pioneer in monoclonal antibody discovery and therapeutic development. At the 17th DDSS, the company will highlight several key services designed to accelerate the drug discovery process:
• Monoclonal Antibody Discovery: Offering custom antibody development services including fully human monoclonal antibody development in 60 days that result in high-affinity, target-specific antibodies for use in drug discovery programs.
• Therapeutic Antibody Development: In addition to the development of fully human monoclonal antibody using humanized mice, Precision also offers antibody humanization and affinity maturation to advanced engineering, Precision Antibody provides end-to-end solutions for therapeutic antibody development.
• Additional Antibody Services: Comprehensive preclinical research services, development of assays for PK studies, and the production of antibodies for biomarker research help researchers fast-track their studies.
Precision Antibody's participation in the summit underscores its leadership in antibody engineering and its ongoing commitment to helping partners bring life-saving therapies to market. Attendees are encouraged to visit the Precision Antibody booth at the exhibition hall, where company representatives will be available to discuss how their antibody solutions can enhance drug discovery efforts.
Join the Innovation at the 17th Drug Discovery Strategic Summit
Don't miss out on the chance to engage with industry leaders, explore cutting-edge technologies, and discover how Precision Antibody can help drive innovation in your drug discovery efforts.
Precision Antibody
9130 Red Branch Road, Suite X, Columbia, MD 21045
Dr. Jun Hayashi
President
Phone: 410-884-4100
Email: info@precisionantibody.com
Precision Antibody
Dr. Jun Hayashi
President
Phone: 410-884-4100
Email: info@precisionantibody.com
Website: www.precisionantibody.com
About Precision Antibody
Founded in 2000, Precision Antibody is a leader in custom monoclonal antibody discovery and development. It provides high-quality, fully customized solutions for researchers in academia, biotech, and pharmaceutical industries. Through innovative technologies and a deep commitment to excellence, Precision Antibody accelerates drug discovery and supports the development of novel therapeutics across a broad range of therapeutic areas.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Precision Antibody Leads the Future of Antibody-Based Therapeutics by Partnering Up with Premier Global Drug Discovery Forum here
News-ID: 3699037 • Views: …
More Releases from Precision Antibody
Precision Antibody's CEO to Speak at 23rd BioPharma Drug Discovery Nexus in San …
Columbia, MD-May 5, 2025-Precision Antibody, a trusted leader in the development of custom monoclonal antibodies, proudly announces that its CEO, Dr. Ginette Serrero, will speak at the upcoming 23rd BioPharma Drug Discovery Nexus, taking place May 7-8, 2025, at Embassy Suites by Hilton in San Francisco, California.
The BioPharma Drug Discovery Nexus (DDN) is an international forum that brings together top experts, researchers, and innovators in drug discovery and development. The…
More Releases for Discovery
Drug Discovery Services Market
The drug discovery process plays a crucial role in the development of new therapeutic treatments for various diseases. The drug discovery services market has witnessed significant growth over the years, driven by advancements in technology, an increasing focus on personalized medicine, and the rising demand for new drugs. This market is composed of a wide range of service providers who offer services across different stages of the drug discovery process,…
Electronic Discovery Market to See Huge Growth by 2030 | AccessData, Advanced Di …
Advance Market Analytics published a new research publication on "Electronic Discovery Market Insights, to 2030" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Electronic Discovery market was mainly driven by the increasing R&D spending across the world.
Get inside Scoop of the report, request…
Q-GEMSF New Antimony Discovery Acquisition Plus Adjacent New Hydrogen Discovery
Vancouver, British Columbia, Canada - September 9, 2024 - Infinity Stone Ventures Corp., announces today that it has acquired a 100-per-cent interest in separate ground areas, located on the Gaspe Peninsula of Quebec, Canada, that covers the two historic reported highest values of Antimony assayed in steam sediment samples ever recorded in Quebec, and a separate land package North of Ville - Marie, Quebec, adjacent Quebec Innovative Materials Corp., ("CSE-QiMC")…
Drug Discovery Technologies Market: Exploring Drug Discovery Technologies with O …
Allied Market Research recently said Drug discovery is the process of identifying and developing new medications for the treatment of diseases. It involves a complex and challenging process that requires extensive research and development. However, advancements in drug discovery technologies are revolutionizing the way we develop medicines, making the process faster, more efficient, and more cost-effective. One of the most significant advances in drug discovery technologies is the use of…
Electronic Discovery Market Will Hit Big Revenues In Future | Conduent, Advanced …
Advance Market Analytics published a new research publication on “Global Electronic Discovery Market Insights, to 2027” with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Electronic Discovery market was mainly driven by the increasing R&D spending across the world.
Some of the key players profiled…
E-Discovery Market Future Prospects 2026 | Logikcull, Advanced Discovery, Cloudn …
The latest update of Global E-Discovery Market study provides comprehensive information on the development activities by industry players, growth opportunities and market sizing for E-Discovery, complete with analysis by key segments, leading and emerging players, and geographies. The 110 page study covers the detailed business overview of each profiled players, its complete research and market development history with latest news and press releases. The study helps in identifying and tracking…
